Literature DB >> 10178664

An introduction to Markov modelling for economic evaluation.

A Briggs1, M Sculpher.   

Abstract

Markov models are often employed to represent stochastic processes, that is, random processes that evolve over time. In a healthcare context, Markov models are particularly suited to modelling chronic disease. In this article, we describe the use of Markov models for economic evaluation of healthcare interventions. The intuitive way in which Markov models can handle both costs and outcomes make them a powerful tool for economic evaluation modelling. The time component of Markov models can offer advantages of standard decision tree models, particularly with respect to discounting. This paper gives a comprehensive description of Markov modelling for economic evaluation, including a discussion of the assumptions on which the type of model is based, most notably the memoryless quality of Markov models often termed the 'Markovian assumption'. A hypothetical example of a drug intervention to slow the progression of a chronic disease is employed to demonstrate the modelling technique and the possible methods of analysing Markov models are explored. Analysts should be aware of the limitations of Markov models, particularly the Markovian assumption, although the adept modeller will often find ways around this problem.

Entities:  

Mesh:

Year:  1998        PMID: 10178664     DOI: 10.2165/00019053-199813040-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

1.  The iterative use of economic evaluation as part of the process of health technology assessment.

Authors:  M Sculpher; M Drummond; M Buxton
Journal:  J Health Serv Res Policy       Date:  1997-01

2.  Discounting and health benefits: another perspective.

Authors:  J Cairns
Journal:  Health Econ       Date:  1992-04       Impact factor: 3.046

3.  Timing and timeliness in medical care evaluation.

Authors:  B S Bloom; A M Fendrick
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

4.  A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions.

Authors:  M Sculpher; J Michaels; M McKenna; J Minor
Journal:  Int J Technol Assess Health Care       Date:  1996       Impact factor: 2.188

5.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

6.  Determining transition probabilities: confusion and suggestions.

Authors:  D K Miller; S M Homan
Journal:  Med Decis Making       Date:  1994 Jan-Mar       Impact factor: 2.583

7.  Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis.

Authors:  D Torgerson; C Donaldson; D Reid
Journal:  J Health Serv Res Policy       Date:  1996-07

8.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

Authors:  D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

Review 10.  Deciphering death: a commentary on Gompertz (1825) 'On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies'.

Authors:  Thomas B L Kirkwood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-19       Impact factor: 6.237

View more
  228 in total

1.  Development of the health and economic consequences of smoking interactive model.

Authors:  M E Orme; S L Hogue; L M Kennedy; A C Paine; C Godfrey
Journal:  Tob Control       Date:  2001-03       Impact factor: 7.552

Review 2.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 3.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

4.  Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.

Authors:  Steven M Kymes; Michael R Plotzke; Michael A Kass; Michael V Boland; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2010-05

5.  Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

Authors:  Takeru Shiroiwa; Yoshiharu Motoo; Kiichiro Tsutani
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

Review 6.  Benefit-risk analysis : a brief review and proposed quantitative approaches.

Authors:  William L Holden
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Cost-effectiveness of spironolactone in patients with severe heart failure.

Authors:  L Tilson; B McGowan; M Ryan; M Barry
Journal:  Ir J Med Sci       Date:  2003 Apr-Jun       Impact factor: 1.568

Review 8.  Taking account of future technology in cost effectiveness analysis.

Authors:  Joshua A Salomon; Milton C Weinstein; Sue J Goldie
Journal:  BMJ       Date:  2004-09-25

9.  Cost-effectiveness analysis of the Spanish renal replacement therapy program.

Authors:  Guillermo Villa; Lucía Fernández-Ortiz; Jesús Cuervo; Pablo Rebollo; Rafael Selgas; Teresa González; Javier Arrieta
Journal:  Perit Dial Int       Date:  2011-09-30       Impact factor: 1.756

10.  Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

Authors:  Junhua Yu; Kenneth J Smith; Diana I Brixner
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.